Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pharmacogenomic assessment of treatment options in gestational diabetes

The Pharmacogenomics Journal volume 5, pages 338–345 (2005)Cite this article

Abstract

Gene expression profiles offer a multidimensional view of metabolic diseases, typically characterized by a single parameter, and can provide a basis for choosing between therapies yielding a common clinical end point. We applied such an approach in gestational diabetes mellitus (GDM). Gene expression was examined in four maternal tissues and placentas from normal patients and euglycemic GDM patients, undergoing elective Cesarean sections at term, treated either by diet or diet plus insulin. Deviations from normal were 11-fold greater for the patients treated by diet, alone, than for patients treated by diet plus insulin. Assuming the achievement of a ‘normal’ gene expression profile, in addition to euglycemia, is a desirable outcome of treatment, insulin treatment appears to have a beneficial effect in the treatment of GDM. Subsequently, we utilized the expression data to identify serum biomarkers that provide ways to monitor the benefits of insulin treatment in GDM.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2003; 26 (Suppl 1): S103–S105.

  2. Farrell M . Improving the care of women with gestational diabetes. MCN Am J Matern Child Nurs 2003; 28: 301–305.

    Article  Google Scholar 

  3. Kjos SL, Buchanan TA . Gestational diabetes mellitus. N Engl J Med 1999; 341: 1749–1756.

    Article  CAS  Google Scholar 

  4. Jovanovic L, Pettitt DJ . Gestational diabetes mellitus. JAMA 2001; 286: 2516–2518.

    Article  CAS  Google Scholar 

  5. Buchanan TA, Xiang A, Kjos SL, Lee WP, Trigo E, Nader I et al. Gestational diabetes: antepartum characteristics that predict postpartum glucose intolerance and type 2 diabetes in Latino women. Diabetes 1998; 47: 1302–1310.

    Article  CAS  Google Scholar 

  6. Dornhorst A, Rossi M . Risk and prevention of type 2 diabetes in women with gestational diabetes. Diabetes Care 1998; 21 (Suppl 2): B43–B49.

    PubMed  Google Scholar 

  7. Kim C, Newton KM, Knopp RH . Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002; 25: 1862–1868.

    Article  Google Scholar 

  8. Major CA, deVeciana M, Weeks J, Morgan MA . Recurrence of gestational diabetes: who is at risk? Am J Obstet Gynecol 1998; 179: 1038–1042.

    Article  CAS  Google Scholar 

  9. Xiong X, Saunders LD, Wang FL, Demianczuk NN . Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes. Int J Gynaecol Obstet 2001; 75: 221–228.

    Article  CAS  Google Scholar 

  10. Hadden DR . When and how to start insulin treatment in gestational diabetes: a UK perspective. Diabet Med 2001; 18: 960–964.

    Article  CAS  Google Scholar 

  11. Damm P . Gestational diabetes mellitus and subsequent development of overt diabetes mellitus. Dan Med Bull 1998; 45: 495–509.

    CAS  PubMed  Google Scholar 

  12. Holness MJ, Langdown ML, Sugden MC . Early-life programming of susceptibility to dysregulation of glucose metabolism and the development of Type 2 diabetes mellitus. Biochem J 2000; 349 (Part 3): 657–665.

    Article  CAS  Google Scholar 

  13. Evans E, Patry R . Management of gestational diabetes mellitus and pharmacists’ role in patient education. Am J Health Syst Pharm 2004; 61: 1460–1465.

    PubMed  Google Scholar 

  14. Albareda M, Caballero A, Badell G, Piquer S, Ortiz A, de Leiva A et al. Diabetes and abnormal glucose tolerance in women with previous gestational diabetes. Diabetes Care 2003; 26: 1199–1205.

    Article  Google Scholar 

  15. Vidaeff AC, Yeomans ER, Ramin SM . Gestational diabetes: a field of controversy. Obstet Gynecol Surv 2003; 58: 759–769.

    Article  Google Scholar 

  16. Adfggf D . Intensive diabetes management: implications of the DCCT and UKPDS. Diabetes Educ 28: 735–740.

  17. Giuffrida FM, Castro AA, Atallah AN, Dib SA . Diet plus insulin compared to diet alone in the treatment of gestational diabetes mellitus: a systematic review. Braz J Med Biol Res 2003; 36: 1297–1300.

    Article  CAS  Google Scholar 

  18. Sameshima H, Kamitomo M, Kajiya S, Kai M, Furukawa S, Ikenoue S . Early glycemic control reduces large-for-gestational-age infants in 250 Japanese gestational diabetes pregnancies. Am J Perinatol 2000; 17: 371–376.

    Article  CAS  Google Scholar 

  19. Langer O . Oral hypoglycemic agents and the pregnant diabetic: ‘from bench to bedside’. Semin Perinatol 2002; 26: 215–224.

    Article  Google Scholar 

  20. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O . A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343: 1134–1138.

    Article  CAS  Google Scholar 

  21. Staudt LM . Molecular diagnosis of the hematologic cancers. N Engl J Med 2003; 348: 1777–1785.

    Article  CAS  Google Scholar 

  22. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947.

    Article  Google Scholar 

  23. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999–2009.

    Article  CAS  Google Scholar 

  24. Nachum Z, Ben-Shlomo I, Weiner E, Shalev E . Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. Br Med J 1999; 319: 1223–1227.

    Article  CAS  Google Scholar 

  25. Turok DK, Ratcliffe SD, Baxley EG . Management of gestational diabetes mellitus. Am Fam Physician 2003; 68: 1767–1772.

    PubMed  Google Scholar 

  26. Shimkets RA, Lowe DG, Tai JT, Sehl P, Jin H, Yang R et al. Gene expression analysis by transcript profiling coupled to a gene database query. Nat Biotechnol 1999; 17: 798–803.

    Article  CAS  Google Scholar 

  27. Lindsey CC, Carter AW, Mangum S, Greene D, Richardson A, Brown SJ et al. A prospective, randomized, multicentered controlled trial to compare the annual outcomes of patients with diabetes mellitus monitored with weekly fructosamine testing versus usual care: a 3-month interim analysis. Diabetes Technol Ther 2002; 4: 637–642.

    Article  Google Scholar 

  28. Chen HS, Chen RL, Chang ZY, Li HD . A comparison of fructosamine and HbA1c for home self-monitoring blood glucose levels in type 2 diabetes. Zhonghua Yi Xue Za Zhi (Taipei) 2002; 65: 151–155.

    Google Scholar 

  29. Pi-Sunyer FX . The epidemiology of central fat distribution in relation to disease. Nutr Rev 2004; 62 (Suppl 7 Part 2): S120–S126.

    Article  Google Scholar 

  30. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET . Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004; 89: 2569–2575.

    Article  CAS  Google Scholar 

  31. Sartipy P, Loskutoff DJ . Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 7265–7270.

    Article  CAS  Google Scholar 

  32. Shanmugam N, Reddy MA, Guha M, Natarajan R . High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003; 52: 1256–1264.

    Article  CAS  Google Scholar 

  33. Takaishi H, Taniguchi T, Takahashi A, Ishikawa Y, Yokoyama M . High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochem Biophys Res Commun 2003; 305: 122–128.

    Article  CAS  Google Scholar 

  34. Christiansen T, Richelsen B, Bruun JM . Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbidly obese subjects. Int J Obes Relat Metab Disord 2005; 29: 146–150.

    Article  CAS  Google Scholar 

  35. Langer O, Yogev Y, Xenakis EM, Brustman L . Overweight and obese in gestational diabetes: the impact on pregnancy outcome. Am J Obstet Gynecol 2005; 192: 1768–1776.

    Article  Google Scholar 

  36. Boney CM, Verma A, Tucker R, Vohr BR . Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 2005; 115: e290–e296.

    Article  Google Scholar 

  37. Ehrenberg HM, Mercer BM, Catalano PM . The influence of obesity and diabetes on the prevalence of macrosomia. Am J Obstet Gynecol 2004; 191: 964–968.

    Article  CAS  Google Scholar 

  38. Gillman MW, Rifas-Shiman S, Berkey CS, Field AE, Colditz GA . Maternal gestational diabetes, birth weight, and adolescent obesity. Pediatrics 2003; 111: e221–e226.

    Article  Google Scholar 

  39. Vohr BR, McGarvey ST, Tucker R . Effects of maternal gestational diabetes on offspring adiposity at 4–7 years of age. Diabetes Care 1999; 22: 1284–1291.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank R Patricelli, Esq., (WHUSA), Dr J M Rothberg (CuraGen) and Dr RA Shimkets (CuraGen) for encouragement and support of this study. We also thank the other physicians and practice managers/coordinators who recruited, tracked and provided clinical information about patients: Mario Cohen, MD, Deborah Hoffman, MD, Helen Trymbulak, MD, Vinay Ranade, MD, Gary Nobert, MD, Neville Graham, MD, Patricia Fagan, MD, Thomas Allan, MD.

Author information

Authors and Affiliations

  1. CuraGen Corporation, Branford, CT, USA

    T Ort, M Voss & A Eisen

  2. Women's Health USA, Inc., Avon, CT, USA

    A Lichtmacher, M Saidel, M DeFrancesco, P Greenberg & B Hunt

Authors
  1. T Ort
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Voss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Lichtmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Saidel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M DeFrancesco
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Greenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Hunt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Eisen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Eisen.

Additional information

DUALITY OF INTEREST

All work reported in this study was sponsored by CuraGen Corporation and performed in collaboration with Women Health Care USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ort, T., Voss, M., Lichtmacher, A. et al. Pharmacogenomic assessment of treatment options in gestational diabetes. Pharmacogenomics J 5, 338–345 (2005). https://doi.org/10.1038/sj.tpj.6500333

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500333

Keywords

Search

Advanced search

Quick links